nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Hypothermia—Metformin—polycystic ovary syndrome	0.0136	0.0788	CcSEcCtD
Brimonidine—Body temperature decreased—Metformin—polycystic ovary syndrome	0.0136	0.0788	CcSEcCtD
Brimonidine—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.013	0.0751	CcSEcCtD
Brimonidine—Apraclonidine—ADRA1A—polycystic ovary syndrome	0.012	0.296	CrCbGaD
Brimonidine—Clonidine—ADRA1D—polycystic ovary syndrome	0.0105	0.259	CrCbGaD
Brimonidine—AOX1—adrenal cortex—polycystic ovary syndrome	0.00899	0.0709	CbGeAlD
Brimonidine—Clonidine—ADRA1B—polycystic ovary syndrome	0.00896	0.221	CrCbGaD
Brimonidine—AOX1—endometrium—polycystic ovary syndrome	0.00803	0.0633	CbGeAlD
Brimonidine—AOX1—uterus—polycystic ovary syndrome	0.0074	0.0584	CbGeAlD
Brimonidine—AOX1—pituitary gland—polycystic ovary syndrome	0.00726	0.0573	CbGeAlD
Brimonidine—AOX1—adipose tissue—polycystic ovary syndrome	0.00723	0.0571	CbGeAlD
Brimonidine—AOX1—adrenal gland—polycystic ovary syndrome	0.00649	0.0512	CbGeAlD
Brimonidine—Nasal congestion—Metformin—polycystic ovary syndrome	0.00608	0.0352	CcSEcCtD
Brimonidine—AOX1—female gonad—polycystic ovary syndrome	0.00605	0.0478	CbGeAlD
Brimonidine—Clonidine—ADRA1A—polycystic ovary syndrome	0.00603	0.149	CrCbGaD
Brimonidine—AOX1—vagina—polycystic ovary syndrome	0.00601	0.0475	CbGeAlD
Brimonidine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.00568	0.0448	CbGeAlD
Brimonidine—Lethargy—Metformin—polycystic ovary syndrome	0.00565	0.0327	CcSEcCtD
Brimonidine—AOX1—endocrine gland—polycystic ovary syndrome	0.00563	0.0444	CbGeAlD
Brimonidine—ADRA2C—endometrium—polycystic ovary syndrome	0.00507	0.04	CbGeAlD
Brimonidine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00495	0.0287	CcSEcCtD
Brimonidine—Influenza—Metformin—polycystic ovary syndrome	0.00479	0.0277	CcSEcCtD
Brimonidine—ADRA2C—uterus—polycystic ovary syndrome	0.00468	0.0369	CbGeAlD
Brimonidine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.00459	0.0362	CbGeAlD
Brimonidine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.00457	0.0361	CbGeAlD
Brimonidine—Drowsiness—Metformin—polycystic ovary syndrome	0.00427	0.0247	CcSEcCtD
Brimonidine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.0041	0.0324	CbGeAlD
Brimonidine—ADRA2A—endometrium—polycystic ovary syndrome	0.00405	0.032	CbGeAlD
Brimonidine—Bradycardia—Metformin—polycystic ovary syndrome	0.0039	0.0226	CcSEcCtD
Brimonidine—Rhinitis—Metformin—polycystic ovary syndrome	0.00384	0.0222	CcSEcCtD
Brimonidine—ADRA2C—female gonad—polycystic ovary syndrome	0.00382	0.0302	CbGeAlD
Brimonidine—ADRA2C—vagina—polycystic ovary syndrome	0.0038	0.03	CbGeAlD
Brimonidine—ADRA2A—uterus—polycystic ovary syndrome	0.00373	0.0294	CbGeAlD
Brimonidine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.00366	0.0289	CbGeAlD
Brimonidine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.00365	0.0288	CbGeAlD
Brimonidine—Eye disorder—Metformin—polycystic ovary syndrome	0.00358	0.0207	CcSEcCtD
Brimonidine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00356	0.0206	CcSEcCtD
Brimonidine—Flushing—Metformin—polycystic ovary syndrome	0.00356	0.0206	CcSEcCtD
Brimonidine—Angiopathy—Metformin—polycystic ovary syndrome	0.00348	0.0201	CcSEcCtD
Brimonidine—Immune system disorder—Metformin—polycystic ovary syndrome	0.00346	0.02	CcSEcCtD
Brimonidine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00345	0.02	CcSEcCtD
Brimonidine—Erythema—Metformin—polycystic ovary syndrome	0.00333	0.0193	CcSEcCtD
Brimonidine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.00327	0.0258	CbGeAlD
Brimonidine—Dysgeusia—Metformin—polycystic ovary syndrome	0.00327	0.0189	CcSEcCtD
Brimonidine—Vision blurred—Metformin—polycystic ovary syndrome	0.00314	0.0182	CcSEcCtD
Brimonidine—Clonidine—CYP1A1—polycystic ovary syndrome	0.00308	0.0757	CrCbGaD
Brimonidine—ADRA2A—female gonad—polycystic ovary syndrome	0.00305	0.0241	CbGeAlD
Brimonidine—ADRA2A—vagina—polycystic ovary syndrome	0.00303	0.0239	CbGeAlD
Brimonidine—Syncope—Metformin—polycystic ovary syndrome	0.00299	0.0173	CcSEcCtD
Brimonidine—Palpitations—Metformin—polycystic ovary syndrome	0.00295	0.0171	CcSEcCtD
Brimonidine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00293	0.017	CcSEcCtD
Brimonidine—Hypertension—Metformin—polycystic ovary syndrome	0.00288	0.0167	CcSEcCtD
Brimonidine—Myalgia—Metformin—polycystic ovary syndrome	0.00284	0.0164	CcSEcCtD
Brimonidine—Chest pain—Metformin—polycystic ovary syndrome	0.00284	0.0164	CcSEcCtD
Brimonidine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.00284	0.0224	CbGeAlD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00282	0.0163	CcSEcCtD
Brimonidine—Discomfort—Metformin—polycystic ovary syndrome	0.00281	0.0162	CcSEcCtD
Brimonidine—Oedema—Metformin—polycystic ovary syndrome	0.00272	0.0158	CcSEcCtD
Brimonidine—Infection—Metformin—polycystic ovary syndrome	0.0027	0.0156	CcSEcCtD
Brimonidine—Shock—Metformin—polycystic ovary syndrome	0.00268	0.0155	CcSEcCtD
Brimonidine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00267	0.0154	CcSEcCtD
Brimonidine—Skin disorder—Metformin—polycystic ovary syndrome	0.00264	0.0153	CcSEcCtD
Brimonidine—Hypotension—Metformin—polycystic ovary syndrome	0.00254	0.0147	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00248	0.0143	CcSEcCtD
Brimonidine—Paraesthesia—Metformin—polycystic ovary syndrome	0.00244	0.0141	CcSEcCtD
Brimonidine—Dyspnoea—Metformin—polycystic ovary syndrome	0.00243	0.014	CcSEcCtD
Brimonidine—Somnolence—Metformin—polycystic ovary syndrome	0.00242	0.014	CcSEcCtD
Brimonidine—Dyspepsia—Metformin—polycystic ovary syndrome	0.0024	0.0139	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00235	0.0136	CcSEcCtD
Brimonidine—Fatigue—Metformin—polycystic ovary syndrome	0.00235	0.0136	CcSEcCtD
Brimonidine—Asthenia—Metformin—polycystic ovary syndrome	0.00195	0.0113	CcSEcCtD
Brimonidine—Pruritus—Metformin—polycystic ovary syndrome	0.00193	0.0111	CcSEcCtD
Brimonidine—Dizziness—Metformin—polycystic ovary syndrome	0.0018	0.0104	CcSEcCtD
Brimonidine—Rash—Metformin—polycystic ovary syndrome	0.00172	0.00993	CcSEcCtD
Brimonidine—Dermatitis—Metformin—polycystic ovary syndrome	0.00171	0.00992	CcSEcCtD
Brimonidine—Headache—Metformin—polycystic ovary syndrome	0.00171	0.00987	CcSEcCtD
Brimonidine—Nausea—Metformin—polycystic ovary syndrome	0.00162	0.00936	CcSEcCtD
Brimonidine—ADRA2A—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000267	0.000405	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000264	0.0004	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000262	0.000398	CbGpPWpGaD
Brimonidine—AOX1—Disease—MTHFR—polycystic ovary syndrome	0.000258	0.000391	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000257	0.00039	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—GNAS—polycystic ovary syndrome	0.000257	0.000389	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000257	0.000389	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PNPLA2—polycystic ovary syndrome	0.000256	0.000388	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000256	0.000387	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000254	0.000385	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HMMR—polycystic ovary syndrome	0.000254	0.000385	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000251	0.00038	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00025	0.000379	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00025	0.000379	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00025	0.000379	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000248	0.000377	CbGpPWpGaD
Brimonidine—AOX1—Disease—IRS2—polycystic ovary syndrome	0.000246	0.000372	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—NCOR1—polycystic ovary syndrome	0.000245	0.000371	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000244	0.000369	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	0.000243	0.000368	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SRD5A1—polycystic ovary syndrome	0.000243	0.000368	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HSD3B1—polycystic ovary syndrome	0.000242	0.000367	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000238	0.000361	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000236	0.000357	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000236	0.000357	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000233	0.000354	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CYP1A1—polycystic ovary syndrome	0.000232	0.000352	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—STAR—polycystic ovary syndrome	0.000232	0.000351	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000228	0.000345	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000228	0.000345	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000227	0.000344	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	0.000227	0.000344	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—GNAS—polycystic ovary syndrome	0.000224	0.00034	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000223	0.000338	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000222	0.000336	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000221	0.000335	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—LHB—polycystic ovary syndrome	0.000221	0.000335	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000221	0.000334	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—MTHFR—polycystic ovary syndrome	0.000216	0.000328	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HSD3B2—polycystic ovary syndrome	0.000216	0.000328	CbGpPWpGaD
Brimonidine—AOX1—Disease—IRS1—polycystic ovary syndrome	0.000215	0.000325	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000214	0.000325	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000214	0.000324	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000213	0.000322	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKR1C1—polycystic ovary syndrome	0.000209	0.000317	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000208	0.000316	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000208	0.000315	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000208	0.000315	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000207	0.000313	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HMMR—polycystic ovary syndrome	0.000206	0.000313	CbGpPWpGaD
Brimonidine—AOX1—Disease—INS—polycystic ovary syndrome	0.000205	0.000311	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000203	0.000308	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FST—polycystic ovary syndrome	0.000203	0.000307	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000202	0.000306	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.0002	0.000304	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.0002	0.000303	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT2—polycystic ovary syndrome	0.000199	0.000301	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LHB—polycystic ovary syndrome	0.000198	0.0003	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HSD3B1—polycystic ovary syndrome	0.000197	0.000298	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000194	0.000295	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000193	0.000293	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—SULT2A1—polycystic ovary syndrome	0.000193	0.000292	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IGF1—polycystic ovary syndrome	0.000192	0.00029	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT2—polycystic ovary syndrome	0.000191	0.00029	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00019	0.000287	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FST—polycystic ovary syndrome	0.000189	0.000287	CbGpPWpGaD
Brimonidine—AOX1—Disease—SERPINE1—polycystic ovary syndrome	0.000189	0.000286	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000188	0.000285	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000187	0.000284	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000187	0.000284	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000187	0.000283	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—RRM2—polycystic ovary syndrome	0.000187	0.000283	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SCT—polycystic ovary syndrome	0.000185	0.000281	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LHB—polycystic ovary syndrome	0.000185	0.00028	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000185	0.00028	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	0.000184	0.000279	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000183	0.000278	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000182	0.000276	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000181	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—YAP1—polycystic ovary syndrome	0.00018	0.000273	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—LHB—polycystic ovary syndrome	0.00018	0.000272	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IGF1—polycystic ovary syndrome	0.000179	0.000271	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT2—polycystic ovary syndrome	0.000179	0.000271	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000177	0.000268	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HSD3B2—polycystic ovary syndrome	0.000176	0.000266	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PPARG—polycystic ovary syndrome	0.000175	0.000266	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000175	0.000265	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000175	0.000265	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000174	0.000264	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SCT—polycystic ovary syndrome	0.000173	0.000263	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—POMC—polycystic ovary syndrome	0.000173	0.000262	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NAMPT—polycystic ovary syndrome	0.000173	0.000262	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000173	0.000262	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000172	0.000261	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—INS—polycystic ovary syndrome	0.000172	0.000261	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000171	0.000259	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP11A1—polycystic ovary syndrome	0.000171	0.000259	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKR1C1—polycystic ovary syndrome	0.00017	0.000258	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—SERPINE1—polycystic ovary syndrome	0.00017	0.000258	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00017	0.000257	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000169	0.000256	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000168	0.000254	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000165	0.00025	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000162	0.000246	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000162	0.000246	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKR1C3—polycystic ovary syndrome	0.000161	0.000244	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000161	0.000244	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000161	0.000244	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000159	0.000241	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP17A1—polycystic ovary syndrome	0.000159	0.00024	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000159	0.00024	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000158	0.000239	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SULT2A1—polycystic ovary syndrome	0.000156	0.000237	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FST—polycystic ovary syndrome	0.000154	0.000233	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000153	0.000232	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000152	0.00023	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—INSR—polycystic ovary syndrome	0.000152	0.00023	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—RRM2—polycystic ovary syndrome	0.000152	0.00023	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00015	0.000228	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LHB—polycystic ovary syndrome	0.00015	0.000228	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000148	0.000225	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000147	0.000222	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—YAP1—polycystic ovary syndrome	0.000146	0.000221	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IGF1—polycystic ovary syndrome	0.000145	0.00022	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT2—polycystic ovary syndrome	0.000145	0.00022	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000144	0.000219	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000142	0.000215	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000142	0.000215	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000142	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—INSR—polycystic ovary syndrome	0.000142	0.000215	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000141	0.000213	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PGR—polycystic ovary syndrome	0.000141	0.000213	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	0.00014	0.000213	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000139	0.000211	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	0.000139	0.00021	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000138	0.000209	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TH—polycystic ovary syndrome	0.000137	0.000208	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000135	0.000204	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000134	0.000203	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—SLC2A4—polycystic ovary syndrome	0.000134	0.000202	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000133	0.000201	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000132	0.0002	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PGR—polycystic ovary syndrome	0.000131	0.000199	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	0.000131	0.000198	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000131	0.000198	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000131	0.000198	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000131	0.000198	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	0.000129	0.000195	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000129	0.000195	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000126	0.000191	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP19A1—polycystic ovary syndrome	0.000126	0.00019	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VEGFA—polycystic ovary syndrome	0.000125	0.00019	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000125	0.000189	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000122	0.000185	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000122	0.000185	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000122	0.000185	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000122	0.000184	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000121	0.000183	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.00012	0.000183	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000118	0.000178	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VEGFA—polycystic ovary syndrome	0.000117	0.000177	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000116	0.000176	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000115	0.000175	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000115	0.000174	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000114	0.000173	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PRL—polycystic ovary syndrome	0.000114	0.000173	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000114	0.000172	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000113	0.000171	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	0.000112	0.00017	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	0.000111	0.000169	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.00011	0.000167	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000109	0.000166	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	0.000108	0.000164	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000108	0.000164	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000108	0.000163	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000107	0.000163	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000107	0.000162	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	0.000107	0.000162	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	0.000107	0.000162	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	0.000107	0.000161	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000103	0.000156	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	0.000102	0.000155	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	0.000101	0.000153	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000101	0.000153	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	0.0001	0.000152	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	9.92e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	9.92e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.56e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.55e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	9.5e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	9.46e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	9.43e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	9.38e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	9.37e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.22e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.18e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	9.1e-05	0.000138	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—polycystic ovary syndrome	8.98e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.93e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	8.76e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	8.73e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	8.67e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	8.67e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	8.65e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.34e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	8.22e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.21e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	8.03e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	7.86e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	7.66e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	7.65e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.61e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	7.54e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	7.5e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	7.5e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	7.34e-05	0.000111	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.25e-05	0.00011	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	7.12e-05	0.000108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	7.01e-05	0.000106	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	6.75e-05	0.000102	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	6.72e-05	0.000102	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	6.55e-05	9.93e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	6.5e-05	9.85e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	6.49e-05	9.84e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	6.31e-05	9.56e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	6.27e-05	9.51e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	6.21e-05	9.42e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.17e-05	9.35e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	6.13e-05	9.29e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.1e-05	9.24e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	6.09e-05	9.24e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	6.07e-05	9.2e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	6.06e-05	9.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	5.96e-05	9.04e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.76e-05	8.73e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.32e-05	8.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	5.12e-05	7.77e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	5.1e-05	7.72e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.97e-05	7.53e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.93e-05	7.47e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.93e-05	7.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.68e-05	7.09e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	4.64e-05	7.03e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.24e-05	6.43e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.96e-05	6.01e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.77e-05	5.71e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.22e-05	4.88e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.93e-05	4.45e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	2.74e-05	4.15e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	2.23e-05	3.37e-05	CbGpPWpGaD
